Press release
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results
Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201
About this update from Absci Corporation
[{"type":"text","content":"Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data demonstrate extended half life and high subcutaneous bioavailability; anticipate Phase 1 initiation in early 2026 Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today reported financial and operating results for the quarter ended March 31, 2025. \"The initiation of our first-in-human study of ABS-101 officially marks Absci’s transition to a clinical-stage biotech company, with ABS-201 also accelerating toward entering the clinic early next year,\" said Sean McClain, Founder and CEO. \"As we continue to execute across our portfolio of wholly owned, partnered, and co-development programs, and with line of sight to additional new partnerships, I am excited for the pivotal updates we expect to share over the rest of this year, and beyond.\" Recent Highlights Initiated dosing of participants in the first-in-human study of ABS-101, a potential best-in-class anti-TL1A antibody. Absci expects to report interim data from the ongoing study in the second half of 2025.Released NHP data for ABS-201 (anti-PRLR) androgenetic alopecia program, demonstrating: Extended half life with potential to translate into Q8W-Q12W dosing intervals in humansHigh subcutaneous bioavailability in NHPs at greater than 90%Excellent manufacturability and developability profile to potentially enable future high concentration formulation of greater than 150mg/mL Internal Pipeline Updates, Anticipated Program Progress, and 2025 Outlook ABS-101 (potential best-in-class anti-TL1A antibody): Today, Absci announced that it has initiated dosing of participants in the first-in-human study of ABS-101. The Phase 1 (ACTRN12625000212459p) randomized, double-blind, placebo-controlled, first-in-human study of single ascending doses of ABS-101 will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers. The study is expected to enroll approximately 40 healthy adult participants. The...